6-(cyclopenten-1-ylamino)-1H-pyrimidin-2-one | 115224-32-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(cyclopenten-1-ylamino)-1H-pyrimidin-2-one
• CAS: 115224-32-3
• 化学式: C₉H₁₁N₃O
• mdl: MFCD24390694
• 分子量: 177.2
• InChiKey: OUANYDIRIBYXIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  53.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] BIOREDUCTIVELY-ACTIVATED PRODRUGS<br/>[FR] PROMÉDICAMENTS ACTIVÉS PAR UNE BIORÉDUCTION
  申请人：ANGIOGENE PHARM LTD

  公开号：WO2006032921A1

  公开（公告）日：2006-03-30

  The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally substituted benzoquinone, optionally substituted naphthoquinone or optionally substituted fused heterocycloquinone; R2 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, aryl or heteroaryl; and R3 is selected such that R3NH2 represents a cytotoxic nucleoside analogue or an ester or phosphate ester prodrug of a cytotoxic nucleoside analogue, with the proviso that if R1 is an aryl group then R2 is not H.

  本发明涉及一种具有如下式（1）的化合物，或其药学上可接受的盐，式中：R1是带有至少一个硝基或偶氮基的取代芳基或杂环芳基，或者是可选择取代的苯醌、可选择取代的萘醌或可选择取代的融合杂环喹啉；R2是H、可选择取代的烷基、可选择取代的烯基、可选择取代的炔基、可选择取代的环烷基、可选择取代的杂环烷基、芳基或杂环芳基；R3被选择为R3NH2，表示细胞毒性核苷类似物或细胞毒性核苷类似物的酯或磷酸酯前药，但如果R1是芳基，则R2不是H。
• [EN] ANTI-VIRAL AND HEPATIC-TARGETED DRUGS<br/>[FR] MÉDICAMENTS ANTIVIRAUX ET CIBLÉS SUR LE FOIE
  申请人：AI BIOPHARMA

  公开号：WO2021074443A1

  公开（公告）日：2021-04-22

  Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and/or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and/or HIV. Formula (I).

  本文揭示了被识别的化合物片段、化合物及其药学上可接受的盐、同位素或溶剂化合物，用作抗病毒药物和/或肝靶向药物，例如用于治疗HBV、HDV和/或HIV。公式（I）。
• [EN] CTPS1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CTPS1 ET LEURS UTILISATIONS
  申请人：NIMBUS CLOTHO INC

  公开号：WO2022087634A1

  公开（公告）日：2022-04-28

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CPTS1, and the treatment of CPTS1-mediated disorders.

  本发明提供了化合物、其组合物以及使用它们抑制CPTS1和治疗CPTS1介导的疾病的方法。
• Compounds, compositions and methods for the treatment of viral infections and other medical disorders
  申请人：Almond R. Merrick

  公开号：US20070003608A1

  公开（公告）日：2007-01-04

  The present application provides methods and compositions for improving the bioavailability of a lipid-containing antiviral compound, and in particular, an antiviral lipid-containing compound. In one embodiment, pharmaceutically acceptable compositions are provided that include an antiviral lipid-containing compound, or salt, ester, or prodrug thereof and one or more bioavailability enhancing compounds, such as inhibitors of cytochrome P450 enzymes.

  本申请提供了一种提高含脂质抗病毒化合物的生物利用度的方法和组合物，尤其是一种含脂质抗病毒化合物。在一种实施例中，提供了药学上可接受的组合物，其中包括一种含脂质抗病毒化合物或其盐、酯或前药，以及一种或多种生物利用度增强化合物，例如细胞色素P450酶抑制剂。
• Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
  申请人：Chu David C.K.

  公开号：US20090270431A1

  公开（公告）日：2009-10-29

  The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR 2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A′ is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A″ is H or OR 1 , with the proviso that when A′ is OR, A is H; and when A is OR 2 , A′ is H; X is C—R 3 or N; Y is C—R 3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R 3 is H or C 1 -C 3 alkyl; D is H or NHR 2 ; E is absent or H; G is O or NHR 2 ; J is N or C—R 4 ; K is N or C—H; R 4 is H, halogen (F, Cl, Br, I), CN, —C(═O)NH 2 , NH 2 , NO 2 , —C═C—H (cis or trans) or —C≡C—H; R a is H or CH 3 ; Each R 1 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R 2 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group; and Pharmaceutically acceptable salts, solvates or polymorphs thereof.

  本发明涉及结构式(I)的化合物，其中B为公式(Ia)，公式(Ib)或公式(Ic)；A为H，OR2或卤素（F，Cl，Br，I，优选F或Br，更优选F）；A′为H，OR2或卤素（F，Cl，Br，I，优选F或Br，更优选F）；A″为H或OR1，但当A′为OR时，A为H；当A为OR2时，A′为H；X为C—R3或N；Y为C—R3或N；优选X或Y为N，且X和Y不同时为N；R3为H或C1-C3烷基；D为H或NHR2；E不存在或为H；G为O或NHR2；J为N或C—R4；K为N或C—H；R4为H，卤素（F，Cl，Br，I），CN，—C（═O）NH2，NH2，NO2，—C═C—H（顺式或反式）或—C≡C—H；Ra为H或CH3；每个R1独立地为H，酰基，C1-C20烷基或醚基，磷酸盐，二磷酸盐，三磷酸盐，磷酸二酯基；每个R2独立地为H，酰基，C1-C20烷基或醚基；以及其药学上可接受的盐，溶剂或多晶形式。